Literature DB >> 22993553

Role of immunohistochemistry and apoptosis as investigative tools in assessing the prognosis of patients with prostate tumours.

Srikumar Chakravarthi1, P M Thani, David Low Wee Yang, Linda Tjoa Husin, Nagaraja Lee.   

Abstract

Apoptosis is a form of programmed cell death necessary for the regulation of the size of organs in adult life. Disruption of apoptotic pathways has been suggested as an important regulatory mechanism in prostatic tumours. The aim of this study was to examine the expression of apoptosis-regulating genes bcl-2 and p53 using immunohistochemistry, and the Gleason score in core needle biopsy specimens of prostate adenocarcinoma. We studied bcl-2 and p53 expression in 30 cases of low-, 30 cases of intermediate- and 20 cases of high-grade prostate adenocarcinoma. Overexpression of bcl-2 and p53 were noted in 54 and 61 of 80 patients (67.5 and 76.25%), respectively. The statistical analysis of the present data suggested that there is significant relation between p53 and bcl-2 expression, and Gleason score in prostate cancer. Thus, immunohistochemistry is a useful investigative parameter in assessing apoptosis to analyse the prognosis of prostatic tumours.

Entities:  

Year:  2010        PMID: 22993553      PMCID: PMC3445942          DOI: 10.3892/etm_00000061

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  18 in total

1.  Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity.

Authors:  G D Grossfeld; A F Olumi; J A Connolly; K Chew; J Gibney; V Bhargava; F M Waldman; P R Carroll
Journal:  J Urol       Date:  1998-05       Impact factor: 7.450

2.  Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

Authors:  J J Bauer; I A Sesterhenn; F K Mostofi; D G McLeod; S Srivastava; J W Moul
Journal:  J Urol       Date:  1996-10       Impact factor: 7.450

Review 3.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

4.  Prognostic significance of Bcl-2 in clinically localized prostate cancer.

Authors:  L Bubendorf; G Sauter; H Moch; P Jordan; A Blöchlinger; T C Gasser; M J Mihatsch
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

5.  p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.

Authors:  N J Prendergast; M R Atkins; E C Schatte; D F Paulson; P J Walther
Journal:  J Urol       Date:  1996-05       Impact factor: 7.450

6.  The biologic dilemma of early carcinoma of the prostate.

Authors:  A C von Eschenbach
Journal:  Cancer       Date:  1996-07-15       Impact factor: 6.860

7.  Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.

Authors:  David C Miller; Khaled S Hafez; Andrew Stewart; James E Montie; John T Wei
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

8.  Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma.

Authors:  H Matsushima; T Kitamura; T Goto; Y Hosaka; Y Homma; K Kawabe
Journal:  J Urol       Date:  1997-12       Impact factor: 7.450

Review 9.  College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group.

Authors:  D J Grignon; E H Hammond
Journal:  Arch Pathol Lab Med       Date:  1995-12       Impact factor: 5.534

10.  p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time.

Authors:  M A Piris; F Pezzella; J C Martinez-Montero; J L Orradre; R Villuendas; M Sanchez-Beato; R Cuena; M A Cruz; B Martinez; F ] Pezella F [corrected to Pezzella
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.